Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
The University of North Carolina Comprehensive Sickle Cell Program
170 Manning DriveChapel Hill, North Carolina, United States
Phone Web
To carry out basic, translational and clinical research in sickle cell disease, The Sickle Cell Program at the University of North Carolina, Chapel Hill is a program created to provide comprehensive care to patients with the various sickle cell syndromes. Sickle cell disease affects approximately 100,000 people in the United States and is most prevalent in young, African American and Latino populations. Our Sickle Cell Clinical Program is staffed by professionals with a commitment to providing the best possible care to patients with sickle cell disease. The adult and pediatric sickle cell staff provides services to more than 300 adults and 250 children annually at our clinics at UNC, Chapel Hill.
MISSION:
-To provide excellent medical care to children and adults with sickle cell disease and related hemoglobinopathies
-To carry out basic, translational and clinical research in sickle cell disease
-To inform patients and their families, health care professionals and the community at large about sickle cell disease
-To provide psychosocial support and advocacy for people with sickle cell disease
-To analyze and improve on the health services systems within which medical care is delivered to children and adults with sickle cell disease
+myBinderRelated Content
-
Johns Hopkins Berman Institute of BioethicsEstablished in 1995, the Berman Institut...
-
George Buchanan, MDDr. George R. Buchanan is a Professor of...
-
Osheiza Abdulmalik, PhDDr. Abdulmalik’s research interests br...
-
Oxygen’s surprisingly complex journey through your body – Enda Butlerhttps://www.youtube.com/watch?v=GVU_zANt...
-
A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)Limited evidence guides opioid dosing st...
-
Ann & Robert H. Lurie Children’s Hospital of ChicagoThe Sickle Cell Disease Program at Ann &...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
